Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Mesothelioma

Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Mesothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's organs. It's usually linked to asbestos exposure. Mesothelioma mainly affects the lining of the lungs (pleural mesothelioma), although it can also affect the lining of the tummy (peritoneal mesothelioma), heart, or testicles.

The four types of mesothelioma are identified by the location in the body where tumors develop. Pleural and peritoneal types of mesothelioma are the most common. Pericardial and testicular mesothelioma accounts for less than 2% of cases combined.

Epidemiology-

According to Thelansis disease modeling data and literature review estimated approximately 3350 cases of malignant mesothelioma are diagnosed annually. In the absence of occupational exposure to asbestos, the incidence is 0.1-0.25 per 100,000 population in both sexes. The risk of mesothelioma is increased in polluted areas by 2-10 fold compared with non-polluted areas. In patients with malignant mesothelioma in the United States, 80% have been exposed to asbestos.

Competitive landscape of Mesothelioma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Mesothelioma 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.
Mesothelioma market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 ONCOFID®-P Fida Farmaceutici Phase 2
2 MTG201 Momotaro-Gene Inc. Phase 2
3 MesoPher Amphera BV Phase 3
4 YS110 Kissei Pharmaceutical Co., Ltd. Phase 2
5 IAG933 Novartis Pharmaceuticals Phase 1
6 Expansion Cohort Oncovir, Inc. Phase 1
7 BBI608 Sumitomo Dainippon Pharma Co., Ltd. Phase 2
8 Pembrolizumab Merck Sharp & Dohme Corp. Phase 1
9 BAY2287411 Bayer Phase 1
10 Nivolumab Injection Bristol-Myers Squibb Phase 3
11 rAd-IFN Trizell Ltd Phase 3
12 Pemetrexed NovoCure Ltd. Phase 2
13 Immunotherapy plus chemotherapy Aduro Biotech, Inc. Phase 1
14 HMPL-453 Hutchison Medipharma Limited Phase 2
15 ONCOS-102 Theradex Phase 2
16 WT-1-vaccine Montanide + GM-CSF Sellas Life Sciences Group Phase 2
17 ADI-PEG 20 plus Pem Cis Polaris Group Phase 3
18 Vorinostat Merck Sharp & Dohme Corp. Phase 3
19 Tazemetostat Epizyme, Inc. Phase 2
20 NGR-hTNF plus Best Investigator's Choice (BIC) AGC Biologics S.p.A. Phase 3
21 Tremelimumab MedImmune LLC Phase 2
22 Avelumab Pfizer Phase 2
23 pemetrexed, cisplatin and CBP501 CanBas Co. Ltd. Phase 2
24 SAR444245 Sanofi Phase 2
25 Vinorelbine Pierre Fabre Laboratories Phase 2
26 Durvalumab PrECOG, LLC. Phase 2
27 Trabectedin PharmaMar Phase 2
28 Bevacizumab and Atezolizumab Hoffmann-La Roche Phase 3
29 cyclophosphamide Atara Biotherapeutics Phase 1
30 Alisertib Millennium Pharmaceuticals, Inc. Phase 2
31 MCY-M11 MaxCyte, Inc. Phase 1
32 VT3989 Vivace Therapeutics, Inc Phase 1
33 αPD1-MSLN-CAR T cells Shanghai Cell Therapy Group Co.,Ltd Phase 1
34 GL-ONC1 Genelux Corporation Phase 1
35 APG-2449 Ascentage Pharma Group Inc. Phase 1
36 S-488210 Shionogi Inc. Phase 1
37 SG001 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 1
38 SCH 721015 Biogen Phase 1
39 SGN-CD228A Seagen Inc. Phase 1
40 INCB001158 Incyte Corporation Phase 2
41 AdV-tk + valacyclovir Candel Therapeutics, Inc. Phase 1
42 gavo-cel TCR2 Therapeutics Phase 2
43 NGM707 NGM Biopharmaceuticals, Inc Phase 2
44 INBRX-109 Inhibrx, Inc. Phase 1
45 VMD-928 VM Oncology, LLC Phase 1
46 CB-839 Calithera Biosciences, Inc Phase 1
47 SO-C101 Sotio a.s. Phase 1
48 QBS10072S Quadriga Biosciences, Inc. Phase 1
49 IOA-244 iOnctura Phase 1
50 ASTX295 Astex Pharmaceuticals, Inc. Phase 2